Carolina Alves Costa Silva, Gianmarco Piccinno, Déborah Suissa, Mélanie Bourgin, Gerty Schreibelt, Sylvère Durand, Roxanne Birebent, Marine Fidelle, Cissé Sow, Fanny Aprahamian, Paolo Manghi, Michal Punčochář, Francesco Asnicar, Federica Pinto, Federica Armanini, Safae Terrisse, Bertrand Routy, Damien Drubay, Alexander M M Eggermont, Guido Kroemer, Nicola Segata, Laurence Zitvogel, Lisa Derosa, Kalijn F Bol, I Jolanda M de Vries
Tumor immunosurveillance plays a major role in melanoma, prompting the development of immunotherapy strategies. The gut microbiota composition, influencing peripheral and tumoral immune tonus, earned its credentials among predictors of survival in melanoma. The MIND-DC phase III trial (NCT02993315) randomized (2:1 ratio) 148 patients with stage IIIB/C melanoma to adjuvant treatment with autologous natural dendritic cell (nDC) or placebo (PL). Overall, 144 patients collected serum and stool samples before and after 2 bimonthly injections to perform metabolomics (MB) and metagenomics (MG) as prespecified exploratory analysis...
February 23, 2024: Nature Communications